INFEX Therapeutics, the biotech firm based at Alderley Park in the North West of England, has closed a $5.9M seed round to accelerate its work on life-threatening infections.
The capital infusion, led by investor Jon Moulton, will fuel the company's expansion beyond pandemic infections. INFEX plans to develop a broader portfolio of new therapies for critical priority infectious diseases, aiming to address unmet patient needs by bringing innovative drugs into clinical trials.














